Work

An Updated Mini-Review on Adverse Effects of Second-Generation Glycopeptide Antibiotics: Telavancin, Dalbavancin and Oritavancin

Year: 2025

Type: review

Abstract: Purpose Glycopeptide antibiotics have saved countless patients from severe bacterial infections. The last two decades have witnessed the launch of second-generation glycopeptide antibiotics, namely telavancin, dalbavancin and oritavancin. Herein, we will highlighted the most common adverse effects of these antibiotics. Methods Compared with the first-generation drugs represented by vancomycin, the successors possess their own advantages. These drugs were approved and considered to be safe, while like all medicines, they may cause adverse effects, which are detrimental to human wellness. However, dalbavancin and oritavancin have not been fully illustrated, especially for special populations. By retrieving the latest literature and case reports, updated data of adverse effects were revealed. Results Based on both clinical trials and real-world experience, although new adverse effects were found, these glycopeptide antibiotics were generally well tolerated. Conclusion In this review, we summarize the latest research progress on the adverse effects of these three second-generation glycopeptide antibiotics.

Source: International Journal of Peptide Research and Therapeutics

DOI: 10.1007/s10989-025-10694-2

Authors: Zixuan Yan, Hui Chen, Ping Zeng, Wei Liu

Institutions: Qilu University of Technology, Qilu Institute of Technology, Chinese University of Hong Kong

Language: English

Topic: Pharmacovigilance and Adverse Drug Reactions

Subfield: Toxicology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,890